Anzeige
Meldung des Tages: DiagnosTear Technologies: Zwei Durchstarter für 2026?!
Werbung
Attraktive Knock-Outs auf Sanofi SA
Typ Hebel Bid / Ask WKN
Call
11,4 0,71 € / 0,73 €
CL5WYF
Typ Hebel Bid / Ask WKN
Put
5,3 1,54 € / 1,56 €
SX25M7
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Sanofi SA

Sanofi Aktie

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Pharmazeutika Land:  Frankreich
95,28 $
-1,185 $
-1,23%
80,939 € 24.12.25
Depot/Watchlist
Marktkapitalisierung *
102,65 Mrd. €
Streubesitz
43,33%
KGV
21,07
Dividende
3,92 €
Dividendenrendite
4,80%
neu: Nachhaltigkeits-Score
68 %
Index-Zuordnung
Euro Stoxx 50
Weiter abwärts? Short handeln - Jetzt mit Hebel 8,55: UJ6RCV
Werbung

Ad-hocs

08.04.25 - GlobeNewswire
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in ...
03.04.25 - GlobeNewswire
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-...
28.03.25 - GlobeNewswire
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-​lowering therapy in hemophilia, offers ...
28.03.25 - GlobeNewswire
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-​ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal ...
26.03.25 - GlobeNewswire
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to ...
25.03.25 - GlobeNewswire
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
24.03.25 - GlobeNewswire
Press Release: Availability of the Q1 2025 Aide mémoire
Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025 . Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the ...
20.03.25 - GlobeNewswire
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to ...
08.03.25 - GlobeNewswire
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Dupixent late-​breaking positive pivotal data in bullous pemphigoid presented at AAD
05.03.25 - GlobeNewswire
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
Sanofi successfully prices EUR 1.5 billion of bond issue
25.02.25 - GlobeNewswire
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma  Approval offers access to new treatment options for newly diagnosed MM patients Approval based ...
22.02.25 - GlobeNewswire
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
ECCO 2025: new duvakitug data reinforce best-​in-class potential in ulcerative colitis and Crohn’s disease
19.02.25 - GlobeNewswire
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Sanofi and CD&R sign Opella share purchase agreement
18.02.25 - GlobeNewswire
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the ...
13.02.25 - GlobeNewswire
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025 . Sanofi announces today the ...
13.02.25 - GlobeNewswire
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn’t ...
07.02.25 - GlobeNewswire
Press Release: Execution of a share buyback agreement for up to €2 billion
Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 , Sanofi announced its intention to execute a share buyback program in ...
03.02.25 - GlobeNewswire
Press Release: Sanofi announces buy back of shares from L’Oréal
Sanofi announces buy back of shares from L’Oréal
31.01.25 - GlobeNewswire
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
30.01.25 - GlobeNewswire
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

Newssuche

Videos

newspaper
26.12.25
Viper Strike Strategie Intro
Strategie-​Paket inklusive Live Online-​Schulung am 4.1. JETZT buchbar ... Mehr »
Anzeige

Aktie im Fokus

DiagnosTear Technologies
DiagnosTear Technologies Inc
0,352 €
-3,83%
DiagnosTear Technologies Inc Chart
Zwei Durchstarter für 2026?!
Mehr zur Aktie »